SuperworthVertex Pharmaceuticals EPS VRTX
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $17.18
- Latest quarter, Q2 FY26
- $4.31
- +8% on a year earlier
- Fiscal year 2025
- $15.33
Vertex Pharmaceuticals' earnings per share was $17.18 over the twelve months to Jun 30, 2026, up 23% on a year earlier.
In its latest quarter, Q2 FY26, it was $4.31, up 8% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 8% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $15.33 | n/a |
| FY2024 | −$2.20 | −116% |
| FY2023 | $13.89 | +8% |
| FY2022 | $12.83 | +42% |
| FY2021 | $9.03 | −12% |
| FY2020 | $10.30 | +128% |
| FY2019 | $4.51 | −44% |
| FY2018 | $8.08 | +677% |
| FY2017 | $1.04 | n/a |
| FY2016 | −$0.46 | n/a |
| FY2015 | −$2.30 | n/a |
| FY2014 | −$3.14 | n/a |
| FY2013 | −$2.04 | n/a |
| FY2012 | −$0.50 | −1350% |
| FY2011 | $0.04 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $4.31 | +8% | $17.18 | |
| Q1 FY26 | $4.02 | +61% | $16.86 | |
| Q4 FY25 | $4.65 | +33% | $15.33 | |
| Q3 FY25 | $4.20 | +5% | $14.18 | |
| Q2 FY25 | $3.99 | n/a | $13.99 | |
| Q1 FY25 | $2.49 | −41% | −$3.92 | |
| Q4 FY24 | $3.50 | −6% | −$2.20 | |
| Q3 FY24 | $4.01 | +1% | −$1.99 | |
| Q2 FY24 | −$13.92 | −495% | −$2.03 | |
| Q1 FY24 | $4.21 | +57% | $15.41 | |
| Q4 FY23 | $3.71 | +18% | $13.89 | |
| Q3 FY23 | $3.97 | +11% | $13.33 |
Against its peers
Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| VRTXVertex Pharmaceuticals | $17.18 | +23% a year |
| REGNRegeneron Pharmaceuticals | $40.44 | +2% a year |
| ONCBeOne Medicines | $0.43 | |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| INCYIncyte | $7.85 | +78% a year |
| EXELExelixis | $3.18 | +53% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| Peer median | $6.38 |
Where Vertex Pharmaceuticals ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Vertex Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.